返回 Agenda
Session 5: CTIS with One Transition Year Ahead: Sponsor End User Operational and Disclosure Aspects
Session Chair(s)
Scott Feiner
Senior Manager, Trial Disclosure
AbbVie, United States
Ruediger Pankow, DRSC
Clinical Trial Regulatory Consultant | CTIS SME
Independent Consultant, Germany
This session provides general experiences with new trials but also with transition trials on the operational use of the system. Views from commercial and academic sponsors, CROs as well as from the Member States perspective will be shared and discussed.
Speaker(s)
Opening: How is CTIS doing after 2 Years?
Ruediger Pankow, DRSC
Independent Consultant, Germany
Clinical Trial Regulatory Consultant | CTIS SME
Industry Perspective
Gabriella Di Matteo
Pfizer, Belgium
Director CTRO Team Manager
CRO Experience
Fatima Pimentel
Syneos Health, Spain
Director, Regulatory Consulting
Academia Perspective
Andrea Seidel-Glaetzer, MA, RN
Coordination Centre For Clinical Trials Heidelberg (KKS), Germany
Head of Project Management
CA Experience – As panelist
Marianne Lunzer, DrMed
AGES, Austria
Assessor, Dept of Clinical Trials, Federal Office for Safety in Health Care